473930-22-2
473930-22-2 structure
- Name: SM-276001
- Chemical Name: SM-276001
- CAS Number: 473930-22-2
- Molecular Formula: C16H21N7O
- Molecular Weight: 327.38
- Catalog: Signaling Pathways Immunology/Inflammation IFNAR
- Create Date: 2020-06-01 14:20:05
- Modify Date: 2024-01-02 16:52:59
-
SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer[1][2].
| Name | SM-276001 |
|---|
| Description | SM-276001 is a potent selective TLR7 agonist that can induce antitumor immune responses. SM-276001 is an orally active interferon (IFN) inducer[1][2]. |
|---|---|
| Related Catalog | |
| Target |
TLR7; IFN[1][2] |
| In Vitro | SM-276001 (1 nM-10 μM) dose-dependently activates NF-κB through human TLR7[2]. |
| In Vivo | SM-276001 demonstrates potent IFN-inducing activity at a dose of 0.1 mg/kg by oral administration in mice[1]. Oral administration of SM-276001, leads to the induction of an inflammatory cytokine and chemokine milieu and to the activation of a diverse population of immune effector cells including T and B lymphocytes, NK and NKT cells[2]. SM-276001 (3 mg/kg PO biweekly) significantly inhibits tumor growth in the Renca renal cell cancer and CT26 colorectal models[2]. SM-276001 (orally; 0.1, 1 or 10 mg/kg) leads to the activation of a diverse population of spleen-resident immune effector cells in Balb/c and C57BL/6J mice. When administered at 1 mg/kg or greater, the plasma concentration of SM-276001 exceeds the MEC of 30 nM[2]. Animal Model: C57BL/6 and B6C3F1 mice bearing Renca or CT26 tumors[2] Dosage: 3 mg/kg Administration: Oral administration twice weekly for 25 days Result: Significantly reduced disease burden in mice bearing either Renca or CT26 tumors. |
| References |
| Molecular Formula | C16H21N7O |
|---|---|
| Molecular Weight | 327.38 |